{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T17:03:37Z","timestamp":1770224617596,"version":"3.49.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009109","name":"Pharmaceuticals Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009109","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007210","name":"Varian Medical Systems","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007210","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007234","name":"University of Chicago","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007234","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009947","name":"Merck Sharp and Dohme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009947","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019851","name":"Aldeyra Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019851","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014487","name":"Clovis Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014487","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016915","name":"Inventiva Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010477","name":"Intuitive Surgical","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010477","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012747","name":"Douglas Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.jtho.2019.08.012","type":"journal-article","created":{"date-parts":[[2019,8,27]],"date-time":"2019-08-27T11:53:10Z","timestamp":1566906790000},"page":"1718-1731","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee \u2013 International Association for the Study of Lung Cancer \u2013 Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting"],"prefix":"10.1016","volume":"14","author":[{"given":"Ritu R.","family":"Gill","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne S.","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hedy L.","family":"Kindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William G","family":"Richards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"III","given":"Samuel G.","family":"Armato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roslyn J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel R.","family":"Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Rimner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"II","given":"Charles B.","family":"Simone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"de Perrot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gideon","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex A.","family":"Adjei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Bueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr.","given":"David H.","family":"Harpole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Hesdorffer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fred R.","family":"Hirsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harvey I.","family":"Pass","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Yorke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Rosenzweig","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bryan","family":"Burt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dean A.","family":"Fennell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolf","family":"Lindwasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shakun","family":"Malik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"Peikert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron S.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Salgia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haining","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerie W.","family":"Rusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna K.","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2019.08.012_bib1","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ctrv.2007.07.012","article-title":"Assessment of tumor response in malignant pleural mesothelioma","volume":"33","author":"Ceresoli","year":"2007","journal-title":"Cancer Treatment Rev"},{"key":"10.1016\/j.jtho.2019.08.012_bib2","doi-asserted-by":"crossref","first-page":"W125","DOI":"10.2214\/AJR.09.3519","article-title":"Diffusion-weighted MRI of malignant pleural mesothelioma: preliminary assessment of apparent diffusion coefficient in histologic subtypes","volume":"195","author":"Gill","year":"2010","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtho.2019.08.012_bib3","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.lungcan.2013.08.005","article-title":"Imaging in pleural mesothelioma: a review of the 11th International Conference of the International Mesothelioma Interest Group","volume":"82","author":"Armato","year":"2013","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.012_bib4","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1148\/radiol.12110872","article-title":"Malignant pleural disease: diagnosis by using diffusion-weighted and dynamic contrast-enhanced MR imaging\u2014initial experience","volume":"263","author":"Coolen","year":"2012","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2019.08.012_bib5","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.2967\/jnumed.107.042333","article-title":"Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans","volume":"48","author":"Francis","year":"2007","journal-title":"J\u00a0Nuc Med"},{"key":"10.1016\/j.jtho.2019.08.012_bib6","doi-asserted-by":"crossref","first-page":"4587","DOI":"10.1200\/JCO.2006.06.8999","article-title":"Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose","volume":"24","author":"Ceresoli","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1148\/rg.241035058","article-title":"Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET","volume":"24","author":"Wang","year":"2004","journal-title":"Radiographics"},{"key":"10.1016\/j.jtho.2019.08.012_bib8","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1053\/j.semtcvs.2009.06.011","article-title":"Current trends in radiologic management of malignant pleural mesothelioma","volume":"21","author":"Gill","year":"2009","journal-title":"Semin Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2019.08.012_bib9","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/jnci\/djx175","article-title":"Quantitative clinical staging for patients with malignant pleural mesothelioma","volume":"110","author":"Gill","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.jtho.2019.08.012_bib10","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01428-2016","article-title":"Impact of tumour thickness on survival after radical radiation and surgery in malignant pleural mesothelioma","volume":"49","author":"de Perrot","year":"2017","journal-title":"Eur Respiratory J"},{"key":"10.1016\/j.jtho.2019.08.012_bib11","doi-asserted-by":"crossref","first-page":"359","DOI":"10.2214\/AJR.11.7015","article-title":"Epithelial malignant pleural mesothelioma after extrapleural pneumonectomy: stratification of survival with CT-derived tumor volume","volume":"198","author":"Gill","year":"2012","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtho.2019.08.012_bib12","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1053\/sonc.2002.30228","article-title":"The role of imaging in malignant pleural mesothelioma","volume":"29","author":"Marom","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.mric.2008.03.004","article-title":"MR imaging of benign and malignant pleural disease","volume":"16","author":"Gill","year":"2008","journal-title":"Magn Reson Imaging Clin N Am"},{"key":"10.1016\/j.jtho.2019.08.012_bib14","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1016\/j.athoracsur.2005.06.014","article-title":"Extended surgical staging for potentially resectable malignant pleural mesothelioma","volume":"80","author":"Rice","year":"2005","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2019.08.012_bib15","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.jtcvs.2005.02.051","article-title":"Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy","volume":"130","author":"Alvarez","year":"2005","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2019.08.012_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/BF02305768","article-title":"Laparoscopy: an important tool in the staging of malignant pleural mesothelioma","volume":"3","author":"Conlon","year":"1996","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib17","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1007\/s00330-008-0918-9","article-title":"Therapy response in malignant pleural mesothelioma-role of MRI using RECIST, modified RECIST and volumetric approaches in comparison with CT","volume":"18","author":"Plathow","year":"2008","journal-title":"Eur Radiol"},{"key":"10.1016\/j.jtho.2019.08.012_bib18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.acra.2007.12.014","article-title":"Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34)","volume":"15","author":"Giesel","year":"2008","journal-title":"Acad Radiol"},{"key":"10.1016\/j.jtho.2019.08.012_bib19","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.ejrad.2007.08.010","article-title":"Morphologic and functional imaging of malignant pleural mesothelioma","volume":"64","author":"Yamamuro","year":"2007","journal-title":"Eur J Radiol"},{"key":"10.1016\/j.jtho.2019.08.012_bib20","doi-asserted-by":"crossref","first-page":"20170814","DOI":"10.1259\/bjr.20170814","article-title":"(18)F-FDG PET\/CT in the management of patients with malignant pleural mesothelioma being considered for multimodality therapy: experience of a tertiary referral center","volume":"91","author":"Elliott","year":"2018","journal-title":"Br J Radiol"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2019.08.012_bib21","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.lungcan.2005.03.007","article-title":"The role of PET in the surgical management of malignant pleural mesothelioma","volume":"49","author":"Flores","year":"2005","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.012_bib22","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1158\/1078-0432.CCR-09-2313","article-title":"A\u00a0novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters","volume":"16","author":"Nowak","year":"2010","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jtho.2019.08.012_bib23","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.jtcvs.2006.03.068","article-title":"Positron emission tomography predicts survival in malignant pleural mesothelioma","volume":"132","author":"Flores","year":"2006","journal-title":"J\u00a0Thorac Cardiovasc Surg"},{"key":"10.1016\/j.jtho.2019.08.012_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.cpet.2011.04.001","article-title":"Multimodality imaging review of malignant pleural mesothelioma diagnosis and staging","volume":"6","author":"Gerbaudo","year":"2011","journal-title":"PET Clin"},{"key":"10.1016\/j.jtho.2019.08.012_bib25","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1007\/s00259-013-2561-1","article-title":"The association of 18F-FDG PET\/CT parameters with survival in malignant pleural mesothelioma","volume":"41","author":"Klabatsa","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.08.012_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/PAS.0000000000000134","article-title":"Prognostic significance of adenocarcinoma in situ, minimally invasive adenocarcinoma, and nonmucinous lepidic predominant invasive adenocarcinoma of the lung in patients with stage I disease","volume":"38","author":"Kadota","year":"2014","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.jtho.2019.08.012_bib27","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1007\/s00259-018-4056-6","article-title":"FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients","volume":"45","author":"Incerti","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.08.012_bib28","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ctrv.2011.01.001","article-title":"Advances in the biology of malignant pleural mesothelioma","volume":"37","author":"Zucali","year":"2011","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.jtho.2019.08.012_bib29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00259-014-2960-y","article-title":"Quantitative analyses at baseline and interim PET evaluation for response assessment and outcome definition in patients with malignant pleural mesothelioma","volume":"42","author":"Lopci","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.08.012_bib30","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.lungcan.2018.01.014","article-title":"Early contrast enhancement: a novel magnetic resonance imaging biomarker of pleural malignancy","volume":"118","author":"Tsim","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.012_bib31","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","article-title":"FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0","volume":"42","author":"Boellaard","year":"2015","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.08.012_bib32","first-page":"885","article-title":"Procedure guideline for tumor imaging with 18F-FDG PET\/CT 1.0","volume":"47","author":"Delbeke","year":"2006","journal-title":"J\u00a0Nucl Med"},{"key":"10.1016\/j.jtho.2019.08.012_bib33","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1007\/s00259-017-3853-7","article-title":"EANM\/EARL FDG-PET\/CT accreditation \u2014 summary results from the first 200 accredited imaging systems","volume":"45","author":"Kaalep","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.08.012_bib34","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1093\/annonc\/mdh059","article-title":"Modified RECIST criteria for assessment of response in malignant pleural mesothelioma","volume":"15","author":"Byrne","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib35","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0959-8049(99)00229-4","article-title":"Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group","volume":"35","author":"Young","year":"1999","journal-title":"Eur J Cancer"},{"issue":"suppl 1","key":"10.1016\/j.jtho.2019.08.012_bib36","doi-asserted-by":"crossref","first-page":"122S","DOI":"10.2967\/jnumed.108.057307","article-title":"From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors","volume":"50","author":"Wahl","year":"2009","journal-title":"J\u00a0Nuc Med"},{"key":"10.1016\/j.jtho.2019.08.012_bib37","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib38","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jtho.2016.04.027","article-title":"North American Multicenter Volumetric CT Study for Clinical Staging of Malignant Pleural Mesothelioma: feasibility and logistics of setting up a quantitative imaging study","volume":"11","author":"Gill","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib39","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1016\/j.jtho.2016.09.121","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the N descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Rice","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib40","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1016\/j.jtho.2016.08.147","article-title":"The IASLC Mesothelioma Staging Project: proposals for revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for pleural mesothelioma","volume":"11","author":"Nowak","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib41","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1016\/j.jtho.2016.09.124","article-title":"The IASLC Mesothelioma Staging Project: proposals for the M descriptors and for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for mesothelioma","volume":"11","author":"Rusch","year":"2016","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib42","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.athoracsur.2016.06.069","article-title":"A\u00a0multicenter study of volumetric computed tomography for staging malignant pleural mesothelioma","volume":"102","author":"Rusch","year":"2016","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jtho.2019.08.012_bib43","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1097\/00005382-199710000-00002","article-title":"Transthoracic needle biopsy: an overview","volume":"12","author":"Klein","year":"1997","journal-title":"J\u00a0Thorac Imaging"},{"key":"10.1016\/j.jtho.2019.08.012_bib44","doi-asserted-by":"crossref","first-page":"581","DOI":"10.2214\/ajr.164.3.7863875","article-title":"Interventional radiology of the chest: image-guided percutaneous drainage of pleural effusions, lung abscess, and pneumothorax","volume":"164","author":"Klein","year":"1995","journal-title":"AJR Am J Roentgenol"},{"key":"10.1016\/j.jtho.2019.08.012_bib45","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1002\/jso.25241","article-title":"Success of genomic profiling of non\u2013small cell lung cancer biopsies obtained by trans-thoracic percutaneous needle biopsy","volume":"118","author":"Gill","year":"2018","journal-title":"J\u00a0Surg Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib46","doi-asserted-by":"crossref","first-page":"31745","DOI":"10.1038\/srep31745","article-title":"Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment","volume":"6","author":"Lizotte","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtho.2019.08.012_bib47","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0169-5002(03)00292-7","article-title":"Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma","volume":"43","author":"van Klaveren","year":"2004","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.012_bib48","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.lungcan.2015.08.012","article-title":"Response evaluation in mesothelioma: beyond RECIST","volume":"90","author":"Cheng","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.012_bib49","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/JTO.0b013e31828354c8","article-title":"Lung volume measurements as a surrogate marker for patient response in malignant pleural mesothelioma","volume":"8","author":"Labby","year":"2013","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib50","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/j.jtho.2018.04.034","article-title":"Revised Modified Response Evaluation Criteria in Solid Tumors for Assessment of Response in Malignant Pleural Mesothelioma (Version 1.1)","volume":"13","author":"Armato","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib51","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jtho.2018.05.003","article-title":"Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): a step forward in a long race","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib52","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.mayocp.2018.01.032","article-title":"Effects of reduction in tumor burden on survival in epithelioid malignant pleural mesothelioma","volume":"93","author":"Mansfield","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jtho.2019.08.012_bib53","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-017-3687-3","article-title":"Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments","volume":"44","author":"Pinker","year":"2017","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.jtho.2019.08.012_bib54","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1148\/radiol.2016142043","article-title":"Practical PERCIST: a simplified guide to PET Response Criteria in Solid Tumors 1.0","volume":"280","author":"O","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.jtho.2019.08.012_bib55","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1183\/09031936.00146110","article-title":"Volumetry: an alternative to assess therapy response for malignant pleural mesothelioma?","volume":"38","author":"Frauenfelder","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jtho.2019.08.012_bib56","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.lungcan.2015.07.011","article-title":"Imaging in pleural mesothelioma: a review of the 12th International Conference of the International Mesothelioma Interest Group","volume":"90","author":"Armato","year":"2015","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2019.08.012_bib57","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1097\/JTO.0b013e318208c83d","article-title":"A\u00a0practical guide of the Southwest Oncology Group to measure malignant pleural mesothelioma tumors by RECIST and modified RECIST criteria","volume":"6","author":"Tsao","year":"2011","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib58","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1470-2045(18)30765-4","article-title":"Nivolumab or nivolumab plus ipilimumab in patients with relapsed\u00a0malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial","volume":"20","author":"Scherpereel","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib59","doi-asserted-by":"crossref","first-page":"S338","DOI":"10.1016\/j.jtho.2018.08.276","article-title":"OA08.02 DREAM \u2014 A phase 2 trial of durvalumab with first line chemotherapy in mesothelioma: final result","volume":"13","author":"Nowak","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2019.08.012_bib60","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JOP.17.00012","article-title":"Treatment of malignant pleural mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline summary","volume":"14","author":"Kindler","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.jtho.2019.08.012_bib61","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1016\/j.jtho.2018.08.2036","article-title":"Current and future management of malignant mesothelioma: a consensus report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation","volume":"13","author":"Tsao","year":"2018","journal-title":"J\u00a0Thorac Oncol"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419306951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086419306951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:40:31Z","timestamp":1761561631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086419306951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":61,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["S1556086419306951"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2019.08.012","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee \u2013 International Association for the Study of Lung Cancer \u2013 Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2019.08.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}